- Iron eliminated more efficiently through renal and fecal routes
- Reduced frequency of injections and reduced treatment time
- Improved localization to areas of iron build-up
Erythropoietic hemochromatosis is typically caused by other blood-centric diseases, like sickle cell anemia and thalassemia. Sickle cell anemia is caused by the abnormal shape of the hemoglobin in the blood. Thalassemia is caused by a reduced production of hemoglobin. Typically, both of these diseases would cause low iron, but to combat both diseases, multiple blood infusions are often needed. These blood infusions are then what cause erythropoietic hemochromatosis.
Erythropoietic hemochromatosis is typically treated using deferoxamine therapy. Deferoxamine is typically administered intravenously. These procedures are costly, and patients have to
receive them over the course of eight to twelve hours, five to seven days a week. This treatment also can cause many negative side effects, including injection site reactions, blurred vision, dizziness, ringing in the ears, flushing, itching, numbness, diarrhea, nausea, upset stomach, or reddish urine.
A UGA researcher has created a technology that better utilizes deferoxamine to target the areas of high iron build-up for people suffering from erythropoietic hemochromatosis.
Using polyrotaxanes as a delivery system for the deferoxamines shows significant benefits over the traditional way of administering deferoxamine. The hPR-DFO reduces the frequency of required treatments, because higher doses can be administered, and it circulates throughout the body for longer. Side effects were also dramatically reduced, going from very significant effects to the organs to virtually none. The formula allows for the excess iron to travel to the liver, where the iron is eliminated through both renal and fecal routes. The researcher also envisionsa patch could be created to even more effectively distribute the treatment
Hematological disorders treatment